{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:22:13Z","timestamp":1778743333232,"version":"3.51.4"},"reference-count":33,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: The standard treatment protocol for PIPAC consists of three procedures. Completion of treatment has been shown to be prognostic of improved survival. The aim of this study was to identify predictors for completion of treatment. Methods: Retrospective multicentric cohort study of patients with peritoneal metastases undergoing PIPAC in three PIPAC expert centers. Per protocol (PP) treatment was defined as patients receiving \u22653 PIPACs and was compared to patients receiving &lt;3. Results: Overall, 183 patients had 517 PIPACs. The main reasons for stopping PIPAC were disease progression in 50% patients, bowel obstruction in 15%, patient\u2019s refusal to pursue in 10%, conversion to cytoreductive surgery in 7%, and medical reasons in 8%. Overall, 95 patients (52%) had PP treatment. The PP median OS was 17 vs. 7 months, p = 0.001. PP patients had r ascites (410 \u00b1 100 mL vs. 960 \u00b1 188 mL, p = 0.001), no prior history of bowel obstruction (12% vs. 24%, p = 0.028), and more bimodal treatment (39% vs. 13%, p &lt; 0.001). After multiple regression, bimodal treatment was found as an independent predictive factor for completing PP (OR = 4.202, 95%CI [1.813, 10.630], p &lt; 0.001), along with prior bowel obstruction (OR = 0.389, 95%CI [0.153, 0.920], p = 0.037). Conclusion: The absence of ascites and prior bowel obstruction can help to select patients suitable for PIPAC. Best results seem to be achieved when PIPAC is combined with systemic chemotherapy.<\/jats:p>","DOI":"10.3390\/cancers14102557","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T22:57:22Z","timestamp":1653346642000},"page":"2557","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases"],"prefix":"10.3390","volume":"14","author":[{"given":"Aur\u00e9lie","family":"Balmer","sequence":"first","affiliation":[{"name":"Department of Visceral Surgery, Faculty of Biology and Medicine UNIL, Lausanne University Hospital (CHUV), Rue du Bugnon 46, 1011 Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9285-3312","authenticated-orcid":false,"given":"Daniel","family":"Clerc","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery, Faculty of Biology and Medicine UNIL, Lausanne University Hospital (CHUV), Rue du Bugnon 46, 1011 Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Toussaint","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery, Faculty of Biology and Medicine UNIL, Lausanne University Hospital (CHUV), Rue du Bugnon 46, 1011 Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Sgarbura","sequence":"additional","affiliation":[{"name":"Surgical Oncology Department, Montpellier Cancer Institute (ICM), University of Montpellier, F-34298 Montpellier, France"},{"name":"Institut de Recherche en Canc\u00e9rologie de Montpellier (IRCM), INSERM U1194, Universit\u00e9 de Montpellier, F-34298 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1036-6474","authenticated-orcid":false,"given":"Abdelkader","family":"Ta\u00efbi","sequence":"additional","affiliation":[{"name":"Digestive Surgery Department, Dupuytren Limoges University Hospital, CNRS, XLIM, UMR 7252, F-87000 Limoges, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4521-8279","authenticated-orcid":false,"given":"Martin","family":"H\u00fcbner","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery, Faculty of Biology and Medicine UNIL, Lausanne University Hospital (CHUV), Rue du Bugnon 46, 1011 Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9786-5208","authenticated-orcid":false,"given":"Hugo","family":"Teixeira Farinha","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery, Faculty of Biology and Medicine UNIL, Lausanne University Hospital (CHUV), Rue du Bugnon 46, 1011 Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1002\/ijc.25596","article-title":"Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: A population-based study","volume":"128","author":"Lemmens","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1200\/JOP.2017.024588","article-title":"Many Challenges of Peritoneal Carcinomatosis","volume":"13","author":"Sasson","year":"2017","journal-title":"J. Oncol. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/bjs.8679","article-title":"Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer","volume":"99","author":"Segelman","year":"2012","journal-title":"Br. J. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-1-4613-1245-1_13","article-title":"Peritoneal carcinomatosis: Natural history and rational therapeutic interventions using intraperitoneal chemotherapy","volume":"81","author":"Sugarbaker","year":"1996","journal-title":"Cancer Treat. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","article-title":"Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: First evidence for efficacy","volume":"21","author":"Solass","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","article-title":"Pressurised intraperitoneal aerosol chemotherapy: Rationale, evidence, and potential indications","volume":"20","author":"Alyami","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/bjs.10521","article-title":"Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis","volume":"104","author":"Grass","year":"2017","journal-title":"Br. J. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejso.2020.08.020","article-title":"Current practice of pressurized intraperitoneal aerosol chemotherapy (PIPAC): Still standardized or on the verge of diversification?","volume":"47","author":"Sgarbura","year":"2021","journal-title":"Eur J. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ejso.2017.03.019","article-title":"Pressurized IntraPeritoneal Aerosol Chemotherapy\u2014Practical aspects","volume":"43","author":"Hubner","year":"2017","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_10","first-page":"4596176","article-title":"Impact of Pressurized Intraperitoneal Aerosol Chemotherapy on Quality of Life and Symptoms in Patients with Peritoneal Carcinomatosis: A Retrospective Cohort Study","volume":"2017","author":"Grass","year":"2017","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Taibi, A., Sgarbura, O., Hubner, M., Bardet, S.M., Alyami, M., Bakrin, N., Durand Fontanier, S., Eveno, C., Gagniere, J., and Pache, B. (2022). Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy with or without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study. Ann. Surg. Oncol., 1\u20139.","DOI":"10.1245\/s10434-022-11577-2"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1245\/s10434-020-09332-6","article-title":"Pressurized Intraperitoneal Aerosol Chemotherapy Enhanced by Electrostatic Precipitation (ePIPAC) for Patients with Peritoneal Metastases","volume":"28","author":"Taibi","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/j.ejso.2021.12.190","article-title":"Treatment response after Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for peritoneal metastases of colorectal origin","volume":"48","author":"Hubner","year":"2022","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/j.ejso.2021.12.324","article-title":"Assessment of treatment response after Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for appendicular peritoneal metastases","volume":"48","author":"Somashekhar","year":"2022","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.21037\/jgo-20-257","article-title":"Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) in patients with colorectal peritoneal metastases-a systematic review","volume":"12","author":"Lurvink","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1515\/pp-2016-0011","article-title":"Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: Proposal of the Peritoneal Regression Grading Score (PRGS)","volume":"1","author":"Solass","year":"2016","journal-title":"Pleura Peritoneum"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1515\/pp-2021-0125","article-title":"Consensus statement on safety measures for pressurized intraperitoneal aerosol chemotherapy","volume":"6","author":"Clerc","year":"2021","journal-title":"Pleura Peritoneum"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ygyno.2018.05.001","article-title":"A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis","volume":"150","author":"Tempfer","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_22","unstructured":"(2022, February 12). Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients: NCT03280511, Available online: https:\/\/clinicaltrials.gov."},{"key":"ref_23","unstructured":"(2022, February 15). Adjuvant PIPAC in Gastric Cancer Patients (PIPAC-OPC4): NCT04047004, Available online: https:\/\/clinicaltrials.gov."},{"key":"ref_24","unstructured":"(2022, February 15). Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt\u2014(GASPACCO): NCT04595929, Available online: https:\/\/clinicaltrials.gov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.ejso.2018.02.014","article-title":"Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: An international survey study","volume":"44","author":"Nowacki","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4240\/wjgs.v4.i4.87","article-title":"Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures","volume":"4","author":"Sangisetty","year":"2012","journal-title":"World J. Gastrointest. Surg."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ejso.2021.10.028","article-title":"Consensus guidelines for pressurized intraperitoneal aerosol chemotherapy: Technical aspects and treatment protocols","volume":"48","author":"Hubner","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Ploug, M., Graversen, M., Pfeiffer, P., and Mortensen, M.B. (2020). Bidirectional treatment of peritoneal metastasis with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and systemic chemotherapy: A systematic review. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-6572-6"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.suronc.2020.05.006","article-title":"Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis","volume":"34","author":"Schena","year":"2020","journal-title":"Surg. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1515\/pp-2021-0108","article-title":"The ISSPP PIPAC database: Design, process, access, and first interim analysis","volume":"6","author":"Mortensen","year":"2021","journal-title":"Pleura Peritoneum"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"20180128","DOI":"10.1515\/pp-2018-0128","article-title":"Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) as an outpatient procedure","volume":"3","author":"Graversen","year":"2018","journal-title":"Pleura Peritoneum"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11605-015-2995-9","article-title":"Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis","volume":"20","author":"Nadiradze","year":"2016","journal-title":"J. Gastrointest. Surg."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"101431","DOI":"10.1016\/j.clinre.2020.03.029","article-title":"Reasons for chemotherapy discontinuation and end-of-life in patients with gastrointestinal cancer: A multicenter prospective AGEO study","volume":"45","author":"Palmieri","year":"2021","journal-title":"Clin. Res. Hepatol. Gastroenterol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/10\/2557\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:16:42Z","timestamp":1760138202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/10\/2557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["cancers14102557"],"URL":"https:\/\/doi.org\/10.3390\/cancers14102557","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,23]]}}}